Linnaeus Therapeutics, Inc.
Clinical trials sponsored by Linnaeus Therapeutics, Inc., explained in plain language.
-
New hope for tough melanoma: experimental drug combo enters Late-Stage trial
Disease control Recruiting nowThis study tests a new oral drug, LNS8801, alone or combined with the immunotherapy pembrolizumab, in people with advanced melanoma that has stopped responding to prior treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, LNS8801 plu…
Phase: PHASE2, PHASE3 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 11:25 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called LNS8801, given alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 200…
Phase: PHASE1, PHASE2 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated May 19, 2026 11:59 UTC